Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
NCT ID: NCT01667575
Last Updated: 2013-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
180 participants
INTERVENTIONAL
2012-08-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568
Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
NCT02732249
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05237115
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT04558502
Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication
NCT02175901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 day Quadruple Therapy
Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
Esomeprazole
antisecretary drug of the quadruple therapy
Amoxicillin
antibiotic of the quadruple therapy
Clarithromycin
antibiotic of the quadruple therapy
Bismuth Potassium Citrate
one of a component of a quadruple therapy
10 day Triple therapy
Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
Esomeprazole
antisecretary drug of the quadruple therapy
Amoxicillin
antibiotic of the quadruple therapy
Clarithromycin
antibiotic of the quadruple therapy
14 day quadruple therapy
Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
Esomeprazole
antisecretary drug of the quadruple therapy
Amoxicillin
antibiotic of the quadruple therapy
Clarithromycin
antibiotic of the quadruple therapy
Bismuth Potassium Citrate
one of a component of a quadruple therapy
long duration (14 day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esomeprazole
antisecretary drug of the quadruple therapy
Amoxicillin
antibiotic of the quadruple therapy
Clarithromycin
antibiotic of the quadruple therapy
Bismuth Potassium Citrate
one of a component of a quadruple therapy
long duration (14 day)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. HONG LU
Professor of GI Division
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Lu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rjkls2012004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.